Accutane and Roaccutane
Accutane and Roaccutane are oral treatments based on the active ingredient isotretinooin. Research has shown us that low-dose accutane (around 10mg a day or so) is a viable option for difficult-to-treat rosacea.
Accutane is not a drug to be taken lightly, it can have significant side effects, so make sure you have the support of your doctor, and that they monitor you whilst you are on it.
Recent Rosacea Blog Posts
A new paper that highlights the progress made in recent years by researchers who are seeking to prove that accutane is a viable rosacea treatment. Good News for Accutane Users This growing body of proof is actually quite important because oral isotretinoin is not officially approved as a treatment for rosacea. Doctors can prescribe accutane […]
The Daily Mail has another of its semi-regular stories on Rosacea today. This time the article highlights the use of low dose accutane to treat hyper keratinisation, slow down sebum production, and also serve as an anti-inflammatory and anti-bacterial agent. Why the misery of ‘adult acne’ could be caused by blushing By LAURA TENNANT Last […]
Below is a recent paper suggesting that combining Finacea with Low Dose Accutane is a useful treatment for rosacea concomitant with seborrheic dermatitis. The patient was also suffering from Actinic Keratosis (pre-cancerous skin lesions). The patient experienced relief from both rosacea and seborrheic dermatitis, two conditions that together sometimes prove tricky to treat. Bear in […]
This study as described in a AAD Poster Session, compared 3 different doses of isotretinoin/accutane with a somewhat standard low dose regime of doxycyline. The study was able to show that 0.3mg/kg/day of accutane was as effective as 100mg of Doxycycline for 14 days; followed by 50mg a day thereafter. A dose of accutane of […]
A paper that Rosacea News previewed in November last year: Accutane dose of 22mg a day works best: EADV has now been published in the JDDG: Journal of German Society of Dermatology. As we learned from the EADV paper, the Spanish pharmaceutical company Almirall is hoping to promote their “branded version of isotretinoin in the […]
